Half-Life in Peptide Pharmacology

Half-life (t½) is the time required for the plasma concentration of a drug to decrease by 50%. For peptides, half-life is the primary determinant of dosing frequency — and the central challenge in peptide drug development.

Why peptide half-lives are short

Native peptides have half-lives measured in minutes, not hours. Several factors converge:

• Proteolytic degradation: endopeptidases and exopeptidases in plasma, kidney, and liver cleave peptide bonds rapidly. Unlike small-molecule drugs metabolized by specific CYP enzymes, peptides are substrates for ubiquitous proteases
• Renal clearance: peptides under ~5 kDa are freely filtered by the glomerulus and degraded by brush-border peptidases in the proximal tubule
• Receptor-mediated clearance: binding to target receptors leads to internalization and lysosomal degradation

The result: native GLP-1 has a half-life of ~2 minutes. Native GnRH: 2–4 minutes. Native growth hormone-releasing hormone (GHRH): ~7 minutes. These endogenous peptides work because they are released in pulses at their target tissue — they were never designed for systemic persistence.

Half-life and dosing frequency

The practical rule: a drug reaches steady state after approximately 4–5 half-lives of repeated dosing, and is essentially eliminated after 4–5 half-lives of discontinuation.

| Peptide | Half-life | Dosing frequency |

|---|---|---|

| Native GLP-1 | ~2 minutes | N/A (endogenous) |

| Kisspeptin-10 | ~28 minutes | Single research doses |

| Ipamorelin | ~2 hours | 1–3× daily |

| BPC-157 | ~4 hours (estimated) | 1–2× daily |

| CJC-1295 (no DAC) | ~30 minutes | 1–2× daily |

| CJC-1295-DAC | ~8 days | 1–2× weekly |

| Semaglutide | ~7 days | Once weekly |

| Tirzepatide | ~5 days | Once weekly |

The engineering challenge is clear: transforming a peptide with a 2-minute half-life into one with a 7-day half-life requires fundamental modifications to the molecule.

Engineering strategies to extend half-life

Fatty acid acylation (lipidation)

Attaching a fatty acid chain to the peptide enables non-covalent binding to serum albumin. Albumin-bound peptide is shielded from proteases and is too large for renal filtration. This is the strategy behind semaglutide (C18 fatty diacid) and liraglutide (C16 fatty acid). Semaglutide's additional Aib substitution at position 8 blocks DPP-4 cleavage, and together these modifications extend GLP-1's half-life from 2 minutes to 7 days.

PEGylation

Covalent attachment of polyethylene glycol (PEG) chains increases hydrodynamic radius, reducing renal filtration and proteolytic access. PEGylation is used in several approved protein therapeutics (PEG-interferon, PEG-filgrastim) but less commonly in small peptides due to potential immunogenicity of PEG and reduced receptor binding affinity.

D-amino acid substitution

Replacing L-amino acids with their D-enantiomers renders the peptide bond resistant to most proteases, which are stereospecific for L-amino acids. FOXO4-DRI uses a complete D-retro-inverso strategy. Selective D-amino acid substitutions at protease-susceptible sites are used in several research peptides.

Cyclization

Constraining the peptide backbone into a cyclic structure reduces conformational flexibility and limits protease access. Oxytocin and vasopressin are naturally cyclized via disulfide bonds, which contributes to their relative stability. Synthetic cyclization strategies include head-to-tail, disulfide, and stapled peptide approaches.

Drug Affinity Complex (DAC)

CJC-1295-DAC uses a maleimide-based reactive group that covalently binds to serum albumin after injection. This extends the half-life from ~30 minutes (CJC-1295 without DAC) to ~8 days, enabling weekly dosing. The DAC approach is specific to the CJC-1295 molecule and not widely used in other peptides.

Context-dependent half-life

Reported half-lives can vary significantly based on:

• Route of administration: IV gives the shortest apparent half-life (immediate peak, rapid distribution). SC creates an absorption depot, extending the apparent half-life. Intranasal has unique kinetics with both local and systemic absorption phases
• Species: mouse half-life data does not directly translate to humans due to differences in body size, metabolic rate, and protease activity. BPC-157's half-life is characterized primarily from rat studies
• Dose: some peptides show dose-dependent kinetics — higher doses may saturate clearance mechanisms, prolonging the apparent half-life
• Individual variation: body composition, renal function, and albumin levels affect clearance rates

When evaluating half-life claims for research peptides, always note the species, route, and dose context. A half-life measured by IV bolus in a 25g mouse is not the same parameter as a half-life measured by SC injection in a 70 kg human.